<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.urologytimes.com/view/gedatolisib-plus-darolutamide-early-findings-in-mcrpc</loc>
      <lastmod>2026-11-17T18:53:10.082Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Urology Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T18:53:10.082Z</news:publication_date>
        <news:title><![CDATA[Gedatolisib plus darolutamide: Early findings in mCRPC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/fda-clears-phase-1-2-trial-androgen-receptor-antagonist-mcrpc</loc>
      <lastmod>2026-11-17T17:35:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Urology Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T17:35:00Z</news:publication_date>
        <news:title><![CDATA[FDA clears phase 1/2 trial of androgen receptor antagonist in mCRPC ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/testosterone-screening-and-cardiovascular-safety-in-traverse</loc>
      <lastmod>2026-11-17T16:50:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Urology Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T16:50:00Z</news:publication_date>
        <news:title><![CDATA[Testosterone Screening and Cardiovascular Safety in TRAVERSE]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/beyond-efficacy-cost-and-cognition-guide-arpi-choice-in-mcspc</loc>
      <lastmod>2026-11-17T14:36:49.268Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Urology Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:36:49.268Z</news:publication_date>
        <news:title><![CDATA[Beyond efficacy: Cost and cognition guide ARPI choice in mCSPC ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/bph-treatment-patterns-understanding-regional-differences-in-baseline-ed-treatment</loc>
      <lastmod>2026-11-16T18:30:24.553Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Urology Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T18:30:24.553Z</news:publication_date>
        <news:title><![CDATA[BPH treatment patterns: Understanding regional differences in baseline ED treatment]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/cretostimogene-reduces-recurrence-risk-by-68-in-phase-3-pivot-006-trial-in-nmibc</loc>
      <lastmod>2026-11-16T16:45:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Urology Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:45:00Z</news:publication_date>
        <news:title><![CDATA[Cretostimogene reduces recurrence risk by 68% in phase 3 PIVOT-006 trial in NMIBC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/testosterone-labeling-and-the-fda-expert-panel</loc>
      <lastmod>2026-11-16T15:56:00.991Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Urology Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T15:56:00.991Z</news:publication_date>
        <news:title><![CDATA[Testosterone Labeling and the FDA Expert Panel]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.urologytimes.com/view/rethinking-testosterone-therapy-after-the-fda-label-revisions</loc>
      <lastmod>2026-11-16T14:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Urology Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T14:30:00Z</news:publication_date>
        <news:title><![CDATA[Rethinking Testosterone Therapy After the FDA Label Revisions]]></news:title>
      </news:news>
	</url></urlset>